Erlotinib hydrochloride

Iupac Name：N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride

CAS No.: 183319-69-9

Molecular Weight：429.901

Modify Date.: 2024-03-05 13:43

Introduction: Erlotinib, launched as once daily oral treatment for patients withnon-small-cell lung cancer (NSCLC), is an inhibitor of the epidermal growth factorreceptor (EGFR) tyrosine kinase, and it is the second small-molecule drug tobe marketed with this mechanism of action. Both erlotinib and its predecessor,gefitinib, are members of the anilinoquinazoline class of tyrosine kinase inhibitors.They compete with the binding of ATP to the intracellular tyrosine kinase domainof EGFR